Seeking Alpha

Sell-side weighs in as Chelsea Therapeutics soars

  • The sell-side continues to weigh in on Chelsea Therapeutics (CHTP +125.2%) following Thursday's Northera panel.
  • Deutsche's Robyn Karnauskas lifts her target to $5 from $4, but notes the FDA could still decide against approval. Fair value is $8-9 assuming approval.
  • Meanwhile, Wedbush is out reiterating an Outperform rating and an $8 target. "Our impression was that the panel came to appreciate the vagaries of clinical trials for neurological disorders—especially in orphan diseases like NOH," analyst Liana Moussatos says.
Comments (2)
  • With such an overwhelmingly positive panel vote with only one 'no' it would be ridiculous to think that the FDA would say no a second time ~ if so, lawsuit maybe?
    15 Jan, 09:50 AM Reply Like
  • Ridiculous yes, but yesterday was a big surprise. Who is to be trusted nowadays ? To put it even more ridiculous: maybe some panel members bought the stock for $ 2.50. Makes one remind on match-fixing in sportsgames.
    15 Jan, 02:24 PM Reply Like
DJIA (DIA) S&P 500 (SPY)